Safety study of γδ-T cells for advanced bladder cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new type of immune cell therapy (γδ-T cells) for people with advanced bladder cancer that cannot be removed by surgery and has not responded to at least two prior treatments. The goal is to see if the treatment is safe and if it can help shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have advanced bladder cancer (stage III or IV) that cannot be surgically removed and has not responded to at least two prior treatments.
- Your overall health must be good enough for the treatment, as shown by blood tests, liver and kidney function tests, and heart function tests.
- You must have at least one tumor that can be measured on scans.
- You cannot be pregnant, breastfeeding, or have active infections like hepatitis B, C, or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (gamma-delta T cells that have been modified to target PD-1) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if these cells can help your immune system fight the cancer.
This trial tests a new combination of immunotherapy (tislelizumab) plus chemotherapy (cisplatin and gemcitabine) with or without an extra drug (trilaciclib) for people with advanced bladder cancer that hasn't been treated yet. The goal is to see if this combination is safe and helps shrink tumors.
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
This trial tests a new drug, 2141-V11, for people with bladder cancer that has not gone away after standard treatments like BCG therapy. It may help those with non-muscle invasive bladder cancer or, in one group, muscle-invasive bladder cancer, who cannot have or choose not to have bladder removal surgery.
This trial tests a new immune cell therapy (gamma-delta T cells from a healthy donor) for people with glioblastoma that has come back or gotten worse after standard treatment. It aims to see if these cells can help fight the tumor.
This trial tests a new experimental drug combination (BL-B01D1 with a PD-1 immunotherapy) for advanced bladder cancer that has not yet been treated with whole-body therapy. The goal is to see if this combination can shrink tumors and help people live longer without their cancer getting worse.
Hear when a new Advanced Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.